(NASDAQ: LENZ) Lenz Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Lenz Therapeutics's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast LENZ's revenue for 2025 to be $203,215,232, with the lowest LENZ revenue forecast at $154,803,847, and the highest LENZ revenue forecast at $281,461,540. On average, 5 Wall Street analysts forecast LENZ's revenue for 2026 to be $1,326,471,946, with the lowest LENZ revenue forecast at $1,173,413,160, and the highest LENZ revenue forecast at $1,439,675,777.
In 2027, LENZ is forecast to generate $3,389,219,134 in revenue, with the lowest revenue forecast at $2,955,346,170 and the highest revenue forecast at $3,870,096,175.